"Alpharen (Fermagate Tablets), our phosphate binder, has been shown to be safe and effective in treating hyperphosphatemia in phase 2 and 3 trials in stage 5 CKD patients undergoing chronic hemodialysis. We intend to develop Rayaldee and Alpharen to constitute part of the foundation for a new and marketly improved standard of care for CKD patients having SHPT and/or hyperphosphatemia."
This was taken from the 2014 Annual Report. For more information, read the entire report.
I agree with you Anne. This is a stock for investors, and not traders. Dr. Frost is the Warren Buffett of pharma. Those investors with a 2-3 year investment horizon will be richly rewarded. I started to buy this stock 3 years ago, and now things look better that I ever expected back then. The best is yet to come!